NCT00956761

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

This is a trial for annual registration of the updated seasonal influenza vaccine formulation.

Conditions

• Seasonal Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Seasonal Influenza Vaccine (MF59C.1)	1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010

Timeline

• Start date: 2009-06-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2009-08-11
• Last updated: 2016-01-27
• Results posted: 2016-01-27

Locations

2 sites across 1 country: Italy